The efficacy of topical application of the TLR7/8 agonist imiquimod, the only TLR agonist approved by FDA for skin cancer treatment, has been linked to local increase of IFN-I production, recruitment of DC and induction of tumor-reactive CTL (83). This evidence concerns the gene TLR7 and skin neoplasm.